IFM Investors Pty Ltd Boosts Holdings in Boston Scientific Corporation $BSX

IFM Investors Pty Ltd raised its stake in Boston Scientific Corporation (NYSE:BSX) by 2.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 310,126 shares of the medical equipment provider’s stock after acquiring an additional 6,109 shares during the quarter. IFM Investors Pty Ltd’s holdings in Boston Scientific were worth $30,448,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Munro Partners grew its holdings in Boston Scientific by 29.6% during the third quarter. Munro Partners now owns 1,242,080 shares of the medical equipment provider’s stock valued at $121,264,000 after purchasing an additional 283,475 shares during the period. Great Waters Wealth Management increased its holdings in shares of Boston Scientific by 64.0% in the third quarter. Great Waters Wealth Management now owns 5,769 shares of the medical equipment provider’s stock worth $563,000 after purchasing an additional 2,251 shares during the period. Westwind Capital purchased a new position in Boston Scientific in the 3rd quarter worth approximately $13,799,000. Farther Finance Advisors LLC lifted its stake in Boston Scientific by 37.5% during the third quarter. Farther Finance Advisors LLC now owns 17,982 shares of the medical equipment provider’s stock worth $1,756,000 after purchasing an additional 4,903 shares during the last quarter. Finally, Security Financial Services INC. purchased a new stake in Boston Scientific in the third quarter worth approximately $384,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.4%

BSX stock opened at $96.05 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The business has a 50 day moving average of $98.67 and a 200 day moving average of $101.17. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The firm has a market cap of $142.38 billion, a PE ratio of 51.36, a price-to-earnings-growth ratio of 1.94 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue was up 20.3% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of analyst reports. Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Robert W. Baird boosted their price target on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday. Cowen reissued a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Finally, Royal Bank Of Canada upped their target price on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $124.85.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 143,095 shares of company stock worth $14,228,950 over the last 90 days. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.